These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 30917188)

  • 1. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study.
    Bagchi S; Lingaiah R; Mani K; Barwad A; Singh G; Balooni V; Bhowmik D; Agarwal SK
    PLoS One; 2019; 14(3):e0214256. PubMed ID: 30917188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy.
    Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Ohta K; Yachie A
    J Immunol Res; 2020; 2020():4284379. PubMed ID: 32537466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
    Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
    PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy.
    Yasutake J; Suzuki Y; Suzuki H; Hiura N; Yanagawa H; Makita Y; Kaneko E; Tomino Y
    Nephrol Dial Transplant; 2015 Aug; 30(8):1315-21. PubMed ID: 26109484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
    Suzuki H; Allegri L; Suzuki Y; Hall S; Moldoveanu Z; Wyatt RJ; Novak J; Julian BA
    Dis Markers; 2016; 2016():7806438. PubMed ID: 27647947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis.
    Zhang X; Xie X; Shi S; Liu L; Lv J; Zhang H
    Nephrol Dial Transplant; 2020 Dec; 35(12):2117-2123. PubMed ID: 31377786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Biomarker for Post-Transplant Recurrent IgA Nephropathy.
    Temurhan S; Akgul SU; Caliskan Y; Artan AS; Kekik C; Yazici H; Demir E; Caliskan B; Turkmen A; Oguz FS; Sever MS
    Transplant Proc; 2017 Apr; 49(3):541-545. PubMed ID: 28340830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.
    Maixnerova D; Ling C; Hall S; Reily C; Brown R; Neprasova M; Suchanek M; Honsova E; Zima T; Novak J; Tesar V
    PLoS One; 2019; 14(2):e0212254. PubMed ID: 30794576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.
    Yanagawa H; Suzuki H; Suzuki Y; Kiryluk K; Gharavi AG; Matsuoka K; Makita Y; Julian BA; Novak J; Tomino Y
    PLoS One; 2014; 9(5):e98081. PubMed ID: 24858067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.
    Elíasdóttir S; Khramova A; Saeed A; Guron G; Boi R; Mölne J; Ebefors K; Nyström J
    BMC Nephrol; 2023 Jun; 24(1):160. PubMed ID: 37286948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy.
    Camilla R; Suzuki H; Daprà V; Loiacono E; Peruzzi L; Amore A; Ghiggeri GM; Mazzucco G; Scolari F; Gharavi AG; Appel GB; Troyanov S; Novak J; Julian BA; Coppo R
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):1903-11. PubMed ID: 21784819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability.
    Hastings MC; Moldoveanu Z; Julian BA; Novak J; Sanders JT; McGlothan KR; Gharavi AG; Wyatt RJ
    Clin J Am Soc Nephrol; 2010 Nov; 5(11):2069-74. PubMed ID: 20634323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy.
    Sugiyama M; Wada Y; Kanazawa N; Tachibana S; Suzuki T; Matsumoto K; Iyoda M; Honda H; Shibata T
    PLoS One; 2020; 15(4):e0232194. PubMed ID: 32324811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression.
    Zhao N; Hou P; Lv J; Moldoveanu Z; Li Y; Kiryluk K; Gharavi AG; Novak J; Zhang H
    Kidney Int; 2012 Oct; 82(7):790-6. PubMed ID: 22673888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.
    Zhang K; Li Q; Zhang Y; Shang W; Wei L; Li H; Gao S; Yan T; Jia J; Liu Y; Lin S
    Kidney Blood Press Res; 2019; 44(5):1196-1206. PubMed ID: 31574506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.
    Moldoveanu Z; Wyatt RJ; Lee JY; Tomana M; Julian BA; Mestecky J; Huang WQ; Anreddy SR; Hall S; Hastings MC; Lau KK; Cook WJ; Novak J
    Kidney Int; 2007 Jun; 71(11):1148-54. PubMed ID: 17342176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.
    Suzuki H; Yasutake J; Makita Y; Tanbo Y; Yamasaki K; Sofue T; Kano T; Suzuki Y
    Kidney Int; 2018 Mar; 93(3):700-705. PubMed ID: 29329643
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Liu XZ; Zhang YM; Jia NY; Zhang H
    Ren Fail; 2020 Nov; 42(1):539-546. PubMed ID: 32524871
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.
    Cassol CA; Bott C; Nadasdy GM; Alberton V; Malvar A; Nagaraja HN; Nadasdy T; Rovin BH; Satoskar AA
    Nephrol Dial Transplant; 2020 Dec; 35(12):2123-2129. PubMed ID: 31369128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy.
    Kim MJ; Schaub S; Molyneux K; Koller MT; Stampf S; Barratt J
    PLoS One; 2016; 11(12):e0166830. PubMed ID: 27930655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.